Phase 2 N=42 Enhancing Extinction Learning in Post Traumatic Stress Disorder (PTSD)
Chronic Posttraumatic Stress Disorder
Primary: PTSD Symptom Severity-Interview (PSS-I) — 32.07; 31.38; 32.73; 17.10 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=291 Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors
Childhood Renal Cell Carcinoma · Clear Cell Renal Cell Carcinoma · Clear Cell Sarcoma of the Kidney
Primary: Event-Free Survival of Patients With Diffuse Anaplastic Wilms' Tumor (DAWT) — 76.1; 25.0; 87.5 Percentage of 4-year OS — p=.0199
Phase 2 N=31 A Study of Oral N-Acetylcysteine in Children With Autism Spectrum Disorders
Autistic Disorder · Asperger Syndrome · Child Development Disorders, Pervasive
Primary: Clinical Global Impression - Severity — 0; 0; 0; 0 Participants
Phase 2 N=13 A Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of a Single Dose of Intravenous TD-8954 Compared With Metoclopramide in Critically Ill Patients With Enteral Feeding Intolerance
Enteral Feeding Intolerance
Primary: Adverse Events — 5; 4 participants
Phase 2 N=40 Azithromycin to Prevent Wheezing Following Severe Respiratory Syncytial Virus (RSV) Bronchiolitis
RSV Bronchiolitis
Primary: IL-8 Concentrations — 12,795; 14,676 Pg/ml — p=0.6
Phase 2 N=400 Efficacy and Safety of AQX-1125 in Unstable COPD
COPD
Primary: The Primary Efficacy Variable Was the AAC for Daily EXACT Scores During the 12-week Treatment Period. — 415.4; 391.7 Area Above Curve on Daily Exact Score — p=0.759
Phase 2 N=69 Concurrent vs. Sequential Sipuleucel-T & Abiraterone Treatment in Men With Metastatic Castrate Resistant Prostate Cancer
Prostate Cancer Metastatic · Hormone Refractory Prostate Cancer · Castration-resistant Prostate Cancer
Primary: Cumulative CD54 Upregulation Ratio Between the Cohorts. — 36.72; 41.61 Ratio ofCD54 molecules on BDS65:FP cells — p=0.2141
Phase 2 N=15 Testosterone Replacement for Male Opioid Agonist Maintained Patients
Chronic Pain · Opioid Addiction · Symptomatic Hypogonadism
Primary: Number of Participants Demonstrating Abstinence — 5; 4 Participants
Phase 2 N=120 Galantamine to Enhance Cognitive Behavioral Therapy for Cocaine Abuse
Cocaine Dependence
Primary: Cocaine Use — 18.82; 14.81; 15.68; 14.85 Days
Phase 2 N=17 A Phase II, Repeat Dose, Proof of Mechanism Study of Losmapimod to Reduce Proteinuria in Patients With Focal Segmental Glomerulosclerosis (FSGS)
Glomerulosclerosis, Focal Segmental
Primary: Number of Participants Meeting the Definition of Responder for Reduction in Proteinuria at the Indicated Time Points — 0; 1; 0; 0 Participants
Phase 2 N=75 Ph II Adjuvant Carboplatin/Docetaxel in Curatively Resected Stage I-IIIA NSCLC
Lung Cancer
Primary: Number of Participants Who Completed Four Cycles of the Carboplatin/Docetaxel Regimen — 57 Participants
Phase 2 N=63 A Randomized Study of Autologous Umbilical Cord Blood Reinfusion in Children With Cerebral Palsy
Cerebral Palsy · CP · Spastic Cerebral Palsy
Primary: Change in Gross Motor Function Measure 66 (GMFM-66) Score — 7.5; 6.9 units on a scale — p=0.72
Phase 2 N=43 Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Bladder Cancer · Bladder (Urothelial, Transitional Cell) Cancer · Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
Primary: Objective Tumor Response — 15 Participants
Phase 2 N=17 Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma
Recurrent Melanoma · Stage IIIB Skin Melanoma · Stage IIIC Skin Melanoma
Primary: Objective Tumor Response (Complete Response and Partial Response) and Progression in Participants With Stage III or IV Melanoma Following Treatment With Temsirolimus and…
Phase 2 N=67 Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults
Malaria
Primary: Number of Subjects With Plasmodium Falciparum Parasitemia Following Sporozoite Challenge — 14; 10; 12 Participants — p=0.7675